Clinical
Trials
At BeiGene, we’re committed to bringing patients worldwide potential treatment options. We are currently recruiting clinical trials across areas including lymphoma, liver cancers, lung cancers, gastric cancers, breast cancers, and more.
-
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
Condition:
Hepatocellular Carcinoma (HCC)
Molecule:Tislelizumab
-
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (TIRHOL)
Condition:
Lymphoma
Molecule:Tislelizumab
-
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Condition:
Advanced Solid Tumor
Molecule:Tislelizumab + BGB-A445
-
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
Condition:
Lupus Nephritis
Molecule:Zanubrutinib
-
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Condition:
Lung Cancer
Molecule:Tislelizumab
-
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
Condition:
Advanced Solid Tumor
Molecule:Tislelizumab
-
Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors
Condition:
Advanced Solid Tumor
Molecule:BGB-A425 + Tislelizumab
-
Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
Condition:
Mature B-cell Malignancies
Molecule:Zanubrutinib
-
Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors
Condition:
Advanced Solid Tumor
Molecule:Tislelizumab
-
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
Condition:
Advanced Solid Tumor
Molecule:Tislelizumab
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.
This list includes trials with the following recruitment statuses: recruiting, enrolling by invitation, study start-up, not yet recruiting, and active/not recruiting.